{"id":"treatment-discontinuation","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL7257","moleculeType":"Small molecule","molecularWeight":"218.30"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This can be due to various reasons such as side effects, lack of efficacy, or personal choice. Treatment discontinuation can impact the effectiveness of the treatment and the patient's overall health outcome.","oneSentence":"Treatment discontinuation is a process where a patient stops taking a medication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:58.672Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment discontinuation in patients with HIV"}]},"trialDetails":[{"nctId":"NCT05622136","phase":"PHASE2","title":"Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2023-09-10","conditions":"Liver Cancer, Hepatocellular Carcinoma","enrollment":28},{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":115},{"nctId":"NCT04958265","phase":"PHASE3","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-11-17","conditions":"Atypical Hemolytic Uremic Syndrome","enrollment":41},{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT07264543","phase":"PHASE2, PHASE3","title":"Early Methylene Blue in the Microhemodynamics of Septic Patients","status":"RECRUITING","sponsor":"Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva","startDate":"2026-01-09","conditions":"Septic Shock, Hypoperfusion","enrollment":50},{"nctId":"NCT06456346","phase":"PHASE3","title":"Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-16","conditions":"Essential Thrombocythemia","enrollment":300},{"nctId":"NCT06459180","phase":"PHASE3","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-24","conditions":"Cervical Cancer","enrollment":686},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":520},{"nctId":"NCT06824467","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-09","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":770},{"nctId":"NCT07293676","phase":"NA","title":"IASTM and Vibration Effects on Pain, Functionality, and Kinesiophobia in Lumbar Disc Herniation","status":"RECRUITING","sponsor":"Istanbul Medipol University Hospital","startDate":"2026-01-05","conditions":"Vibration, Lumbar Disc Herniation, Soft Tissue Mobilization","enrollment":45},{"nctId":"NCT06422143","phase":"PHASE3","title":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-10","conditions":"Non-small Cell Lung Cancer, NSCLC","enrollment":851},{"nctId":"NCT07436728","phase":"PHASE1, PHASE2","title":"A Study of TAK-505 in Adults With Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Takeda","startDate":"2026-04-15","conditions":"Malignant Solid Tumors","enrollment":151},{"nctId":"NCT06312176","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-14","conditions":"Breast Neoplasms","enrollment":1200},{"nctId":"NCT05419024","phase":"PHASE2","title":"Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-01-09","conditions":"HIV","enrollment":50},{"nctId":"NCT06561685","phase":"PHASE1","title":"A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-09-19","conditions":"Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer","enrollment":340},{"nctId":"NCT02477696","phase":"PHASE3","title":"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2015-07-28","conditions":"Chronic Lymphocytic Leukemia","enrollment":533},{"nctId":"NCT05063565","phase":"PHASE2","title":"TheraSphere With Durvalumab and Tremelimumab for HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2023-11-03","conditions":"Hepatocellular Carcinoma","enrollment":100},{"nctId":"NCT06623617","phase":"NA","title":"The Impact of Breathing Training on PPSUI: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Jie Li","startDate":"2025-05-01","conditions":"Stress Urinary Incontinence (SUI)","enrollment":58},{"nctId":"NCT07139873","phase":"PHASE3","title":"A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)","status":"RECRUITING","sponsor":"Dizal (Jiangsu) Pharmaceutical Co., Ltd.","startDate":"2025-09-08","conditions":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":250},{"nctId":"NCT07494448","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-07-01","conditions":"HER 2 Positive Advanced Breast Cancer, Breast Cancer","enrollment":24},{"nctId":"NCT07496281","phase":"PHASE4","title":"OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation","status":"NOT_YET_RECRUITING","sponsor":"Ewha Womans University Mokdong Hospital","startDate":"2027-03-01","conditions":"Atrial Fibrillation (AF), Coronary Artery Disease, Drug-eluting Stent","enrollment":2},{"nctId":"NCT07288034","phase":"PHASE2","title":"Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-09-21","conditions":"Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8","enrollment":535},{"nctId":"NCT04660344","phase":"PHASE3","title":"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-03","conditions":"Muscle-invasive Bladder Cancer","enrollment":761},{"nctId":"NCT07318558","phase":"PHASE3","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-16","conditions":"Ovarian Neoplasms, Ovarian Cancer","enrollment":900},{"nctId":"NCT07227402","phase":"PHASE3","title":"A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-26","conditions":"Renal Cell Carcinoma","enrollment":904},{"nctId":"NCT02682641","phase":"PHASE2","title":"Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2016-05-18","conditions":"Mantle Cell Lymphoma","enrollment":50},{"nctId":"NCT06814145","phase":"PHASE2","title":"Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-16","conditions":"Hypertension, Pulmonary","enrollment":130},{"nctId":"NCT07332507","phase":"PHASE1","title":"Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-05-29","conditions":"Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma","enrollment":30},{"nctId":"NCT07496762","phase":"NA","title":"Effects of Different-Frequency Electroacupuncture on Suprahyoid Muscles in Post-Stroke Dysphagia: Efficacy and Neural Networks","status":"NOT_YET_RECRUITING","sponsor":"Kaili Chen","startDate":"2026-04-21","conditions":"Stroke Sequelae, Deglutition Disorders, Acupuncture Therapy","enrollment":90},{"nctId":"NCT07491913","phase":"NA","title":"Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission","status":"RECRUITING","sponsor":"Marmara University","startDate":"2025-06-15","conditions":"Takayasu Arteritis","enrollment":40},{"nctId":"NCT06863272","phase":"PHASE1, PHASE2","title":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-03","conditions":"Castration-Resistant Prostatic Cancer, Metastasis","enrollment":360},{"nctId":"NCT04185402","phase":"PHASE4","title":"Azithromycin Reduction to Reach Elimination of Trachoma","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-05-29","conditions":"Trachoma","enrollment":3931},{"nctId":"NCT07491874","phase":"NA","title":"Use of Nitrous Oxide for Pain and Anxiety Management During Cervical Cerclage Removal- A Multicenter Randomized Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Kaplan Medical Center","startDate":"2026-05-01","conditions":"Preterm Delivery, Cervical Cerclage, Cervical Insufficiency","enrollment":60},{"nctId":"NCT04208529","phase":"PHASE3","title":"A Long-term Follow-up Study in Participants Who Received CTX001","status":"ENROLLING_BY_INVITATION","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-01-20","conditions":"Beta-Thalassemia, Thalassemia, Sickle Cell Disease","enrollment":160},{"nctId":"NCT07493512","phase":"PHASE1","title":"Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Amgen","startDate":"2026-05-26","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC)","enrollment":40},{"nctId":"NCT07483385","phase":"NA","title":"Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"The General Hospital of Western Theater Command","startDate":"2026-01-13","conditions":"Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation, Hematologic Disorders","enrollment":45},{"nctId":"NCT07123090","phase":"PHASE2","title":"A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Stephanie Berg","startDate":"2025-11-24","conditions":"Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma","enrollment":25},{"nctId":"NCT04323410","phase":"NA","title":"Casting Versus Percutaneus Pinning Treatment of Pediatric Overriding Distal Forearm Fractures","status":"RECRUITING","sponsor":"Töölö Hospital","startDate":"2020-06-29","conditions":"Pediatric Overriding Distal Metaphyseal Radius Fractures","enrollment":60},{"nctId":"NCT06119581","phase":"PHASE3","title":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-12-21","conditions":"Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis","enrollment":1264},{"nctId":"NCT04331041","phase":"PHASE2","title":"Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2021-08-24","conditions":"Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma","enrollment":42},{"nctId":"NCT07489703","phase":"PHASE2","title":"SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-04-30","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT03617679","phase":"PHASE2","title":"Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2019-03-06","conditions":"Metastatic Endometrial Cancer","enrollment":79},{"nctId":"NCT06353386","phase":"PHASE1, PHASE2","title":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-20","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":220},{"nctId":"NCT07490002","phase":"PHASE2","title":"Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2026-04-06","conditions":"Esophageal Squamous Carcinoma","enrollment":33},{"nctId":"NCT07489547","phase":"PHASE2, PHASE3","title":"Medication Withdrawal in Stable HF With Improved LVEF","status":"RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2025-03-01","conditions":"Heart Failure","enrollment":90},{"nctId":"NCT00977977","phase":"PHASE2","title":"Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2010-12-22","conditions":"Nephrotic Syndrome, Proteinuria, Autoimmune Disease","enrollment":30},{"nctId":"NCT04003636","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-24","conditions":"Biliary Tract Carcinoma","enrollment":1069},{"nctId":"NCT07126158","phase":"PHASE2","title":"Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-04-30","conditions":"Pancreatic Adenocarcinoma, Cancer of the Pancreas, Pancreas Cancer","enrollment":36},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT05262764","phase":"","title":"Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-04-15","conditions":"Heart Failure","enrollment":1200},{"nctId":"NCT04008797","phase":"PHASE1, PHASE2","title":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2019-07-11","conditions":"Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular","enrollment":301},{"nctId":"NCT04475510","phase":"NA","title":"Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke","status":"RECRUITING","sponsor":"Josep Rodes-Cabau","startDate":"2020-07-08","conditions":"Patent Foramen Ovale, Ischemic Stroke, Bleeding Ulcer","enrollment":100},{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT06428396","phase":"PHASE2","title":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-27","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT05143840","phase":"PHASE2","title":"Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"RECRUITING","sponsor":"Augusta University","startDate":"2022-04-22","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid","enrollment":100},{"nctId":"NCT06667076","phase":"PHASE2","title":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":480},{"nctId":"NCT06780085","phase":"PHASE2","title":"A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":96},{"nctId":"NCT04542148","phase":"PHASE2","title":"Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-02-10","conditions":"Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk","enrollment":120},{"nctId":"NCT04472598","phase":"PHASE3","title":"Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-09-29","conditions":"Myelofibrosis (MF)","enrollment":252},{"nctId":"NCT05166161","phase":"PHASE3","title":"A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria","status":"ACTIVE_NOT_RECRUITING","sponsor":"PTC Therapeutics","startDate":"2022-02-14","conditions":"Phenylketonuria","enrollment":200},{"nctId":"NCT04462406","phase":"PHASE2","title":"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-09","conditions":"Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":150},{"nctId":"NCT06225167","phase":"","title":"Pharmacist-Driven Stress Ulcer Prophylaxis Minimization in the Intensive Care Unit","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2023-05-13","conditions":"Stress Ulcer","enrollment":120},{"nctId":"NCT05980169","phase":"NA","title":"The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Augusta University","startDate":"2023-11-29","conditions":"Gynecologic Cancer, Neuropathy;Peripheral","enrollment":80},{"nctId":"NCT07486479","phase":"PHASE3","title":"Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-10","conditions":"Acute Myeloid Leukemia (AML)","enrollment":204},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT05319730","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":230},{"nctId":"NCT06997497","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-16","conditions":"Colon Adenocarcinoma, Rectal Adenocarcinoma","enrollment":477},{"nctId":"NCT03323476","phase":"PHASE3","title":"Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Departemental Vendee","startDate":"2018-02-02","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, End Stage Renal Disease","enrollment":136},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT07232602","phase":"PHASE1, PHASE2","title":"KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-09","conditions":"Bladder Cancer","enrollment":55},{"nctId":"NCT05285891","phase":"PHASE4","title":"Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-01-12","conditions":"Multiple Sclerosis","enrollment":123},{"nctId":"NCT04637594","phase":"PHASE3","title":"Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-05-27","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":3},{"nctId":"NCT06882486","phase":"NA","title":"Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy","status":"RECRUITING","sponsor":"Institut Paoli-Calmettes","startDate":"2026-05","conditions":"Kidney Cancer","enrollment":60},{"nctId":"NCT07209111","phase":"PHASE2","title":"A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-04","conditions":"Neoplasm Malignant","enrollment":150},{"nctId":"NCT07190248","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Non-small Cell Lung Cancer","enrollment":675},{"nctId":"NCT05801029","phase":"PHASE2","title":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-07-18","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":60},{"nctId":"NCT07049926","phase":"PHASE1, PHASE2","title":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-20","conditions":"Renal Cell Carcinoma","enrollment":140},{"nctId":"NCT06952504","phase":"PHASE3","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-22","conditions":"Endometrial Cancer","enrollment":1123},{"nctId":"NCT06133062","phase":"PHASE2","title":"Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-11-16","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":45},{"nctId":"NCT04191096","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-12","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1251},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":"Colorectal Neoplasms","enrollment":1000},{"nctId":"NCT06036836","phase":"PHASE2","title":"Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-09-29","conditions":"Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer","enrollment":163},{"nctId":"NCT07017933","phase":"NA","title":"Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes","status":"RECRUITING","sponsor":"3ive Labs","startDate":"2025-07-16","conditions":"Renal Impairment After Cardiac Surgery, Renal Impairment, Acute Kidney Injury","enrollment":124},{"nctId":"NCT07482059","phase":"PHASE1, PHASE2","title":"A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2026-02","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT04083976","phase":"PHASE2","title":"A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-20","conditions":"Advanced Solid Tumor","enrollment":316},{"nctId":"NCT04938817","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-08-19","conditions":"Small Cell Lung Carcinoma","enrollment":110},{"nctId":"NCT07107334","phase":"PHASE2","title":"A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia","status":"RECRUITING","sponsor":"University of Florida","startDate":"2026-03","conditions":"Endometrioid Endometrial Adenocarcinoma","enrollment":20},{"nctId":"NCT03390504","phase":"PHASE3","title":"A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-03-23","conditions":"Urothelial Cancer","enrollment":629},{"nctId":"NCT07279935","phase":"PHASE4","title":"Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-05-31","conditions":"Non-small Cell Lung Cancer","enrollment":100},{"nctId":"NCT06801834","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-04-04","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":695},{"nctId":"NCT03875235","phase":"PHASE3","title":"Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-04-16","conditions":"Biliary Tract Neoplasms","enrollment":810},{"nctId":"NCT07190794","phase":"","title":"RESCUE: Discontinuation of GLP-1","status":"RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2025-12-17","conditions":"Obesity","enrollment":150},{"nctId":"NCT07307170","phase":"NA","title":"The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-12-15","conditions":"Herpes Zoster, Mirogabalin, Pain","enrollment":750},{"nctId":"NCT06780098","phase":"PHASE2","title":"Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-28","conditions":"Lung Neoplasm","enrollment":144},{"nctId":"NCT07477756","phase":"","title":"A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-09-04","conditions":"Prostate Cancer","enrollment":1247},{"nctId":"NCT05529927","phase":"PHASE2","title":"Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Parnassia Addiction Research Centre","startDate":"2026-05","conditions":"Cocaine Use Disorder","enrollment":204},{"nctId":"NCT06846671","phase":"PHASE3","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-04-10","conditions":"CLL, Chronic Lymphocytic Leukemia","enrollment":250},{"nctId":"NCT07205822","phase":"PHASE3","title":"A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-10-30","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT06377852","phase":"PHASE3","title":"The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2024-10-29","conditions":"Metastatic Breast Cancer","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Treatment discontinuation","genericName":"Treatment discontinuation","companyName":"ANRS, Emerging Infectious Diseases","companyId":"anrs-emerging-infectious-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Treatment discontinuation is a process where a patient stops taking a medication. Used for Treatment discontinuation in patients with HIV.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}